{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-25-000026","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.504671+00:00","generated_at":"2026-05-23T05:15:05.248143+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biohaven secures up to $600M non-dilutive financing from Oberland Capital for troriluzole development","bullets":["First tranche $250M funded at closing on or before April 30, 2025.","Second tranche up to $150M available upon FDA approval of troriluzole; third tranche up to $200M for acquisitions.","Oberland receives tiered single-digit royalties on global troriluzole net sales for up to 10 years, capped at multiples.","Additional milestone payment of 35% of funded amount upon FDA or EMA approval.","Proceeds to support ongoing clinical trials and commercialization preparations for troriluzole in SCA."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-25-000026","json":"https://secwatch.observer/filing/0001935979-25-000026.json","markdown":"https://secwatch.observer/filing/0001935979-25-000026.md","text":"https://secwatch.observer/filing/0001935979-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000026/0001935979-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000026/bhvn-20250428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:15:05.248143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}